Jason B Myers

US Patent:

7868014, Jan 11, 2011

Filed:

Oct 13, 2005

Appl. No.:

11/576960

Inventors:

Thomas Charles Britton - Carmel IN, US
Veronique Dehlinger - Basingstoke, GB
Colin Peter Dell - Basingstoke, GB
Bruce Anthony Dressman - Indianapolis IN, US
Jason Kenneth Myers - Indianapolis IN, US
Eric Samuel Nisenbaum - Carmel IN, US

Assignee:

Eli Lilly and Company - Indianapolis IN

International Classification:

C07D 401/04
C07D 409/04
A61K 31/506

US Classification:

514275, 514342, 514343, 514370, 514422, 514426, 544330, 5462711, 5462791, 548198, 548527, 548557

Abstract:

The present invention relates to compounds of the Formula (I) which are useful for treating conditions associated with mGluR3 receptors, such as depression, schizophrenia and migraine, pharmaceutical compositions thereof, and methods of using the same.

US Patent:

8030304, Oct 4, 2011

Filed:

Sep 17, 2007

Appl. No.:

12/377733

Inventors:

Zhaogen Chen - Indianapolis IN, US
Chafiq Hamdouchi Hamdouchi - Carmel IN, US
Erik James Hembre - Indianapolis IN, US
Philip Arthur Hipskind - New Palestine IN, US
Jason Kenneth Myers - Indianapolis IN, US
Takako Takakuwa - Indianapolis IN, US
James Lee Toth - Knightstown IN, US

Assignee:

Eli Lilly and Company - Indianapolis IN

International Classification:

A01N 43/58
A01N 43/54
A01N 43/64
A01N 43/78
A01N 43/56
A61K 31/50
A61K 31/505
A61K 31/41
A61K 31/425
A61K 31/415
C07D 239/42
C07D 401/04
C07D 471/04
C07D 471/22
C07D 487/04

US Classification:

514247, 514256, 514257, 514267, 514359, 514365, 514366, 514403

Abstract:

The present invention relates to compounds of Formula (I), pharmaceutical compositions thereof, and use thereof as corticotropin releasing factor 1 (CRF1) receptor antagonists in the treatment of psychiatric and neuroendocrine disorders, neurological diseases, and metabolic syndrome.

US Patent:

20040157878, Aug 12, 2004

Filed:

Dec 5, 2003

Appl. No.:

10/729529

Inventors:

Bruce Rogers - Mystic CT, US
David Piotrowski - Groton Long Point CT, US
Vincent Groppi - Kalamazoo MI, US
Eric Jacobsen - Chesterfield MO, US
Jason Myers - Indianapolis IN, US
Daniel Walker - Noank CT, US
Donn Wishka - Groton Long Point CT, US
Marc Skaddan - Richland MI, US

International Classification:

C07D471/02
A61K031/4745
A61K031/46

US Classification:

514/303000, 514/304000, 514/305000, 514/412000, 546/118000, 546/125000, 546/135000

Abstract:

Radiolabeled ligands useful as probes for determining the relative abundance, receptor occupancy, and/or function of nicotinic acetylcholine receptors. The compounds of Formula I as described herein are labeled with a radioactive isotopic moiety such as C, F, Br, I or I. Disorders are diagnosed by administering to a mammal a detectably labeled compound and detecting the binding of that compound to the nAChR. The compounds that have been administered are detected using methods including, but not limited to, position emission topography and single-photon emission computed tomography. The present invention is useful in diagnosing a wide variety of diseases and disorders as discussed herein.

US Patent:

20050107425, May 19, 2005

Filed:

Oct 12, 2004

Appl. No.:

10/963922

Inventors:

Bruce Rogers - Mystic CT, US
David Piotrowski - Waterford CT, US
Vicent Groppi - Kalamazoo MI, US
Eric Jacobsen - Chesterfield MO, US
Jason Myers - Indianapolis IN, US
Daniel Walker - Mystic CT, US
Donn Wishka - Mystic CT, US

International Classification:

A61K031/4745
A61K031/46
A61K031/407
A61K031/137
A61K031/445

US Classification:

514304000, 514305000, 514412000, 514317000, 514649000

Abstract:

The present invention relates to compositions and methods to treat ADHD with an α7 nAChR full agonist and psychostimulants and/or monoamine reuptake inhibitors.

US Patent:

20080132551, Jun 5, 2008

Filed:

Mar 24, 2004

Appl. No.:

10/808125

Inventors:

Bruce Nelsen Rogers - Mystic CT, US
David Walter Piotrowski - Waterford CT, US
Brandon J. Margolis - Indianapolis IN, US
Jason K. Myers - Indianapolis IN, US
Vincent Edward Groppi - Kalamazoo MI, US
Daniel G. Rudmann - Fishers IN, US

International Classification:

A61K 31/4439
C07D 417/02
C07D 413/02
A61K 31/422
A61P 25/28
A61P 25/00
A61K 31/427
A61K 31/433
C07D 285/12

US Classification:

514342, 5462721, 514340, 5462687, 548146, 514365, 514363, 548136, 514374, 548215

Abstract:

The invention provides compounds of Formula I:wherein A, B, and X are described herein. These compounds may be in the form of pharmaceutical salts or compositions, may be in pure enantiomeric form or racemic mixtures, and are useful in pharmaceuticals used to treat diseases or conditions in which α7 nAChR is known to be involved.

US Patent:

20140076402, Mar 20, 2014

Filed:

Sep 13, 2013

Appl. No.:

14/026130

Inventors:

Jason D. Myers - Alexandria VA, US
Jesse A. Frantz - Landover MD, US
Robel Y. Bekele - Washington DC, US
Jasbinder S. Sanghera - Ashburn VA, US
Ishwar D. Aggarwal - Charlotte NC, US

International Classification:

H01L 31/032
H01L 31/18

US Classification:

136262, 438 95, 136252, 136264

Abstract:

A method for forming a photovoltaic device by depositing at least one wetting layer onto a substrate where the wetting layer is ≦100 nm and sputtering a photovoltaic material onto the wetting layer where the wetting layer interacts with the photovoltaic material. Also disclosed is the related photovoltaic device made by this method. The wetting layer may comprise any combination of InSe, CuSe, CuSe, GaSe, InS, CuS, CuS, GaS, CuInSe, CuGaSe, InGaSewhere 0≦x≦2, CuInS, CuGaS, InGaSwhere 0≦x≦2, InSeSwhere 0≦x≦3, CuSeSwhere 0≦x≦2, CuSeS, (0≦x≦1), GaSeSwhere 0≦x≦3, and InGaSSwhere 0≦x≦2, 0≦y≦3. The photovoltaic material may be a CIGS (copper indium gallium diselenide) material or a variation of a CIGS material where a CIGS component is replaced or supplemented with any combination of sulfur, tellurium, aluminum, and silver.

US Patent:

20220332918, Oct 20, 2022

Filed:

Jun 30, 2022

Appl. No.:

17/855021

Inventors:

- Arlington VA, US
Vinh Q. Nguyen - Fairfax VA, US
Nia A. Pollard - Alexandria VA, US
Frederic H. Kung - Alexandria VA, US
Daniel J. Gibson - Cheverly MD, US
Jason D. Myers - Alexandria VA, US
Colin C. Baker - Alexandria VA, US
Woohong Kim - Lorton VA, US
Jasbinder S. Sanghera - Ashburn VA, US

International Classification:

C08K 3/06
C08F 12/36
C08J 3/24

Abstract:

A polymer comprising one or more chalcogenide elements and one or more crosslinking moieties. The crosslinking moieties may be organic, inorganic, or both. Also disclosed is the related method for making a polymer comprising purifying a chalcogenide polymer powder comprising one or more chalcogenide elements, melting the purified chalcogenide polymer powder, adding one or more crosslinking moieties to the melted chalcogenide polymer, and curing the modified chalcogenide polymer at a temperature between 150 and 200 C.

US Patent:

20220190173, Jun 16, 2022

Filed:

Mar 7, 2022

Appl. No.:

17/688557

Inventors:

- Arlington VA, US
Jasbinder S. Sanghera - Ashburn VA, US
Woohong Kim - Washington DC, US
Colin C. Baker - Alexandria VA, US
Jason D. Myers - Alexandria VA, US
Jesse A. Frantz - Washington DC, US

International Classification:

H01L 31/032
H01L 21/02
H01L 31/0352
H01L 31/18

Abstract:

A composition of matter having a coated silicon substrate with multiple alternating layers of polydopamine and polyallylamine bound copper-indium-gallium oxide (CIGO) nanoparticles on the substrate. A related composition of matter having polyallylamine bound to CIGO nanoparticles to form PAH-coated CIGO nanoparticles. A related CIGO thin film made via conversion of layer-by-layer assembled CIGO nanoparticles and polyelectrolytes. CIGO nanoparticles are created via a flame-spray pyrolysis method using metal nitrate precursors, subsequently coated with polyallylamine (PAH), and dispersed in aqueous solution. Multilayer films are assembled by alternately dipping a substrate into a solution of either polydopamine or polystyrenesulfonate and then in the CIGO-PAH dispersion to fabricate CIGO films as thick as 1-2 microns.